NCT07110571View on ClinicalTrials.gov

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

May 31, 2027

Conditions
Gastric CancerGastroesophageal-junction Cancer
Interventions
DRUG

Adebrelimab Injection

Adebrelimab injection.

DRUG

SHR-A1811 for Injection

SHR-A1811 for injection.

DRUG

SHR-A1904 for Injection

SHR-A1904 for injection.

DRUG

SHR-8068 Injection

SHR-8068 injection.

Trial Locations (2)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

050010

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07110571 - A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | Biotech Hunter | Biotech Hunter